Evaluation of the efficacy and safety of remdesivir in hospitalized patients with a new coronavirus infection COVID-19: data from a Russian university clinic

ABSTRACT

Introduction. The use of remdesivir in patients with the new coronavirus infection COVID-19 is known to improve the prognosis of the disease. But there is not enough data on efficacy and safety of remdesivir use in patients from Russia. Aim. To evaluate the efficacy and safety of remdesivir in patients with COVID-19. Materials and methods. A comparative prospective study was conducted in two parallel groups. The study enrolled 300 patients diagnosed with COVID-19 (grade 1–3 severe pneumonia according to CT scan), who were divided into two groups (n = 150 in each) according to the prescription of remdesivir. Treatment efficacy was assessed by recording cases of disease progression and adverse outcomes. The safety of therapy was assessed by hepatotoxicity and nephrotoxicity. Results. Patients receiving remdesivir were significantly less likely to be transferred to the intensive care unit (OR 0.3884, 95% CI 0.1645–0.9175) and to be on artificial ventilation (OR 0.3830, 95% CI 0.1539–0.9527). Treatment with remdesivir had no significant effect on mortality (OR 0.4932, 95% CI 0.08897–2.7346) and complications (OR 0.4391, 95% CI 0.1623–1.1879), including acute respiratory distress syndrome (OR 0.3919, 95% CI 0.07483–2.0524). The duration of hospitalization was significantly short-er in group 1 patients – 12.2533 days (95% CI 11.4101–13.0966) compared to group 2 – 14.5267 days (95% CI 13.5125–15.5408). Hepatotoxicity with remdesivir (OR 1.5376, 95% CI 0.8035–2.9426), nephrotoxicity (OR 1.6338, 95% CI 0.522–5.1141) were noted, but no statistically significant difference was found (p > 0.05). Conclusions. The addition of remdesivir to the basic regimen of patients with new coronavirus infection COVID-19 improved the course of the disease, reducing the risks of patients being transferred to the intensive care unit and of receiving artificial ventilation. © 2022, Remedium Group Ltd. All rights reserved.